1 – 8 of 8
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
CT-based volumetric measures obtained through deep learning : Association with biomarkers of neurodegeneration
(
- Contribution to journal › Article
- 2021
-
Mark
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
(
- Contribution to journal › Article
- 2020
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
(
- Contribution to journal › Article
- 2018
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018(
- Contribution to conference › Abstract
-
Mark
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression : A study of fully automated immunoassays in BioFINDER and ADNI cohorts
(
- Contribution to journal › Article
-
Mark
Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment
(
- Contribution to journal › Article
- 2016
-
Mark
Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia
(
- Contribution to journal › Article
- 2013
-
Mark
The ELISA-Measured Increase in Cerebrospinal Fluid Tau that Discriminates Alzheimer's Disease from other Neurodegenerative Disorders is not Attributable to Differential Recognition of Tau Assembly Forms
(
- Contribution to journal › Article